#United States #North Carolina #Amgen #Biomanufacturing

Amgen, a leading biotechnology company, has announced an ambitious expansion plan worth $1 billion to establish a second drug substance manufacturing facility in North Carolina. This bold move will boost Amgen's total investment in the region to over $1.5 billion, a significant commitment following a prior investment of $550 million. Amgen's chairman and CEO, Robert A. Bradway, emphasized that this expansion illustrates their dedication to delivering transformative medicines globally. He noted, 'North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact.' The newly planned facility will utilize cutting-edge technologies and sustainable manufacturing practices, reflecting Amgen's commitment to environmental stewardship. This expansion is expected to create 370 new jobs in North Carolina, contributing to the development of a robust biomanufacturing hub in the region. North Carolina has gained recognition as a premier life sciences destination, boasting a skilled and diverse workforce that meets the needs of the biotechnology sector. Governor Roy Cooper praised Amgen's decision, stating, 'North Carolina offers everything an innovative biotech company needs to succeed.' This second facility, alongside the existing one, will enhance Amgen's ability to efficiently produce and deliver high-quality medicines, resonating with the increasing demand in the global market. Amgen has been at the forefront of biopharmaceutical innovation for over four decades, dedicated to combating some of the world's most challenging diseases. With over 40 years in the industry, the company has established a vast portfolio of products targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare conditions. Recently recognized as one of the 'World's Most Innovative Companies' by Fast Company and listed among 'America's Best Large Employers' by Forbes, Amgen continues to set benchmarks in the biotechnology sector. This expansion not only underscores Amgen's dedication to innovation and quality in pharmaceuticals but also strengthens North Carolina's position in the biomanufacturing landscape. By capitalizing on its operational expertise and technological advancements, Amgen aims to ensure the reliable delivery of medications to patients worldwide, thereby solidifying its critical role in the healthcare ecosystem. For more updates on Amgen's initiatives and ongoing advancements, readers can visit the company's official website and follow Amgen's social media channels.